Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

BACKGROUND: Interleukin-2 (IL-2) induces durable objective responses in a small cohort of patients with metastatic renal cell carcinoma (RCC) but the antigen(s) responsible for tumor rejection are not known. 5T4 is a non-secreted membrane glycoprotein expressed on clear cell and papillary RCCs. A mo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kaufman, Howard L, Taback, Bret, Sherman, William, Kim, Dae Won, Shingler, William H, Moroziewicz, Dorota, DeRaffele, Gail, Mitcham, Josephine, Carroll, Miles W, Harrop, Richard, Naylor, Stuart, Kim-Schulze, Seunghee
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2009
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2631474/
https://ncbi.nlm.nih.gov/pubmed/19128501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-7-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak